Barrios, C. H., Hurvitz, S. A., Tolaney, S. M., Cortés, J., Punie, K., Schneeweiss, A., Brufsky, A., Oliveira, M., Sohn, J., Tokunaga, E., Fabi, A., Park, Y. H., Xu, B., Hegg, R., Thakur, M. D., Zhang, Y., Vaksman, N., Lai, C., Bardia, A. (2026). ASCENT-03: Efficacy by biomarker subgroup with sacituzumab govitecan (SG) vs chemotherapy (chemo) in participants (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1014